News
47m
HealthDay on MSNASCO: Vepdegestrant Ups Survival in ER+, HER2− Advanced Breast Cancer With ESR1 MutationsFor patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, the oral proteolysis-targeting chimera ER degrader, vepdegestrant, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results